Partnership and licensing opportunities from Kytopen.
The Flowfect™ technology combines continuous fluid flow with electric fields for high efficiency delivery of payloads such as mRNA, DNA, and CRISPR Cas9 RNP to primary cells. By carefully synchronizing the pulse delivery with the fluid flow we have eliminated the harmful effects of traditional transfection via static electroporation. Our ex vivo cell engineering platform is compatible with primary cells being developed for immuno-oncology and gene editing applications.
This is the Partnership and Licensing section of the company profile page for Kytopen on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.